BeStock  
Stocks › Biotechnology › DNTH

Dianthus Therapeutics DNTH

US equityMarket cap rank #2087Biotechnology
$84.55 −$0.28 (-0.33%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $84.08 -0.56%
Open$83.62
Prev close$84.83
Day range$82.53 – $85.67
Volume799.7K
Market cap$4.76B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$1.21M+205.6% YoY
Operating profit-$58.47M-45.1% YoY
Net profit-$46.64M-26.9% YoY
Diluted EPS-$0.81+16.5% YoY
Free cash flow-$50.70M-65.9% YoY
Operating cash flow-$50.33M

Revenue, last 8 quarters

$1.3MDec '24$1.2MMar '25$193.0KJun '25$396.0KSep '25$284.0KDec '25$463.0KMar '26$761.0KJun '26$1.2MSep '26

Net profit, last 8 quarters

$-28.4MDec '24$-29.5MMar '25$-31.6MJun '25$-36.8MSep '25$-64.4MDec '25$-40.8MMar '26$-50.2MJun '26$-46.6MSep '26

Diluted EPS by quarter

-0.81Dec '24-0.82Mar '25-0.88Jun '25-0.97Sep '25-1.43Dec '25-0.85Mar '26-0.90Jun '26-0.81Sep '26

Free cash flow by quarter

$-27.5MDec '24$-27.7MMar '25$-23.9MJun '25$-30.6MSep '25$-47.1MDec '25$-28.9MMar '26$-49.2MJun '26$-50.7MSep '26

Annual revenue

$1.5MFY21$6.4MFY22$2.8MFY23$6.2MFY24$2.0MFY25

Profitability & balance sheet

Operating margin-8,683.9%
Net margin-7,436.5%
Return on equity-22.6%
Return on assets-21.8%
Return on invested capital-26.5%
Current ratio30.02
Liabilities / assets2.7%
Cash & investments$837.78M
Total debt$859,000.00
Net cash (debt)$836.92M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $1.21M $761,000.00 $463,000.00 $2.04M $284,000.00
Total Operating Revenue $1.21M $761,000.00 $463,000.00 $2.04M $284,000.00
Operating Expense $59.68M $62.24M $47.00M $179.97M $69.83M
Selling and Admin Expenses $14.08M $13.56M $12.47M $34.33M $9.93M
-General & Admin Expense $14.08M $13.56M $12.47M $34.33M $9.93M
Research & Development $45.60M $48.69M $34.53M $145.64M $59.90M
Operating Profit -$58.47M -$61.48M -$46.53M -$177.93M -$69.54M
Net Non-Operating Interest Income (Expense) $12.14M $11.54M $6.27M $16.12M $5.27M
Non-Operating Interest Income $12.14M $11.54M $6.27M $16.12M $5.27M
Other Income (Expense) -$314,000.00 -$275,000.00 -$566,000.00 -$523,000.00 -$158,000.00
Gain on Sale of Security $4,000.00 $95,000.00 -$317,000.00 $451,000.00 $251,000.00
Other Non-Operating Income (Expenses) -$318,000.00 -$370,000.00 -$249,000.00 -$974,000.00 -$409,000.00
Pretax Profit -$46.64M -$50.22M -$40.83M -$162.34M -$64.43M
Net Profit -$46.64M -$50.22M -$40.83M -$162.34M -$64.43M
Profit from Continuing Operations -$46.64M -$50.22M -$40.83M -$162.34M -$64.43M
Net Income to Parent Company -$46.64M -$50.22M -$40.83M -$162.34M -$64.43M
Net Income to Common Stockholders -$46.64M -$50.22M -$40.83M -$162.34M -$64.43M
Basic EPS -$0.81 -$0.90 -$0.85 -$4.20 -$1.43
Diluted EPS -$0.81 -$0.90 -$0.85 -$4.20 -$1.43

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $1.28B $1.21B $1.25B $530.92M $530.92M
Total Current Assets $856.04M $897.54M $1.12B $409.44M $409.44M
Cash and Cash Equivalents & Short-Term Investments $837.78M $886.81M $1.11B $404.30M $404.30M
-Cash and Cash Equivalents $55.69M $110.55M $627.67M $51.09M $51.09M
-Short Term Investments $782.10M $776.26M $483.59M $353.21M $353.21M
Receivables $582,000.00 $106,000.00 $1.23M $52,000.00 $52,000.00
-Accounts Receivable $582,000.00 $106,000.00 $1.23M $52,000.00 $52,000.00
Prepaid Assets $17.50M $10.43M $7.34M $5.01M $5.01M
Other Current Assets $169,000.00 $184,000.00 $83,000.00 $86,000.00 $86,000.00
Total Non-Current Assets $420.21M $315.73M $126.97M $121.48M $121.48M
Net PPE $1.90M $1.64M $1.57M $1.63M $1.63M
-Gross PPE $2.31M $2.01M $1.90M $1.94M $1.94M
-Accumulated Depreciation -$410,000.00 -$373,000.00 -$336,000.00 -$304,000.00 -$304,000.00
Investments and Advances $406.04M $303.63M $113.87M $110.14M $110.14M
-Available for Sale Securities $406.04M $303.63M $113.87M $110.14M $110.14M
Other Non-Current Assets $12.27M $10.46M $11.54M $9.72M $9.72M
Total Liabilities $34.82M $41.25M $45.57M $37.52M $37.52M
Total Current Liabilities $28.52M $34.39M $38.28M $30.73M $30.73M
Payables $5.50M $6.39M $5.27M $9.73M $9.73M
-Accounts Payable $5.50M $6.39M $5.27M $9.73M $9.73M
Current Accrued Expenses $13.55M $20.49M $28.43M $9.94M $9.94M
Short-Term Debt and Capital Lease Obligation $349,000.00 $374,000.00 $399,000.00 $367,000.00 $367,000.00
-Current Capital Lease Obligation $349,000.00 $374,000.00 $399,000.00 $367,000.00 $367,000.00
Current Deferred Liabilities $1.59M $1.52M $1.49M $1.19M $1.19M
Total Non-Current Liabilities $6.31M $6.86M $7.29M $6.79M $6.79M
Long Term Debt and Capital Lease Obligation $859,000.00 $913,000.00 $965,000.00 $1.02M $1.02M
-Long Term Capital Lease Obligation $859,000.00 $913,000.00 $965,000.00 $1.02M $1.02M
Non-Current Deferred Liabilities $5.45M $5.94M $6.32M $5.77M $5.77M
Total Equity $1.24B $1.17B $1.20B $493.40M $493.40M
Stockholders' Equity $1.24B $1.17B $1.20B $493.40M $493.40M
Capital Stock $56,000.00 $55,000.00 $54,000.00 $43,000.00 $43,000.00
-Common Stock $56,000.00 $55,000.00 $54,000.00 $43,000.00 $43,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $1.72B $1.60B $1.58B $829.60M $829.60M
Retained Earnings -$474.42M -$427.78M -$377.56M -$336.73M -$336.73M
Gains/Losses Not Affecting Retained Earnings -$6.28M -$2.13M -$575,000.00 $489,000.00 $489,000.00
-Due from Related Parties Current – – – $0.00 $0.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$50.33M -$48.98M -$28.86M -$129.06M -$46.98M
Net cash flow from continuing operations -$50.33M -$48.98M -$28.86M -$129.06M -$46.98M
Net Income from Continuing Operations -$46.64M -$50.22M -$40.83M -$162.34M -$64.43M
Gain/Loss from Continuing Operations -$28,000.00 -$105,000.00 $302,000.00 -$507,000.00 -$253,000.00
Depreciation & Depletion & Amortization $109,000.00 $107,000.00 $76,000.00 $428,000.00 $97,000.00
Change in Working Capital -$15.61M -$5.01M $2.22M $16.73M $12.48M
-Change in Receivables -$476,000.00 $1.12M -$1.18M $755,000.00 $4.95M
-Change in Prepaid Assets -$7.06M -$3.20M -$2.33M -$235,000.00 $1.12M
-Change in Payables and Accrued Expense -$5.99M -$3.78M $7.00M $11.28M $6.68M
-Change in Other Current Assets -$1.66M $1.18M -$2.12M $358,000.00 -$207,000.00
-Change In Other Working Capital -$430,000.00 -$339,000.00 $849,000.00 $4.57M -$64,000.00
Net cash flow from investing -$111.87M -$478.52M -$133.97M -$122.83M $37.20M
Net Cash Flow from Continuing Investing Activities -$111.87M -$478.52M -$133.97M -$122.83M $37.20M
Capital Expenditure -$368,000.00 -$181,000.00 -$10,000.00 -$213,000.00 -$138,000.00
Net Investment Purchase and Sale -$111.51M -$478.34M -$133.96M -$122.62M $37.34M
Financing Cash Flow $107.47M $10.38M $739.41M $280.13M $4.88M
Net Cash Flow from Continuing Financing Activities $107.47M $10.38M $739.41M $280.13M $4.88M
Net Common Stock Issuance $98.07M $0.00 $736.36M $272.27M $0.00
Proceeds from Stock Option Exercised $9.41M $10.58M $4.40M $8.22M $5.08M
Net Other Financing Charges $0.00 -$201,000.00 -$1.34M -$364,000.00 -$192,000.00
Ending Cash Balance $55.98M $110.72M $627.84M $51.25M $51.25M
Net Change in Cash -$54.74M -$517.12M $576.58M $28.23M -$4.90M
Beginning Cash Balance $110.72M $627.84M $51.25M $23.02M $56.15M
Free Cash Flow -$50.70M -$49.16M -$28.87M -$129.27M -$47.12M

Discussion

No comments yet — be the first to weigh in on DNTH.

Sign in to join the discussion.

Scroll to Top